Advice

following a full submission assessed under the ultra-orphan medicine process:

letermovir (Prevymis®) is accepted for use within NHSScotland.

Indication under review: for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).

Letermovir, compared with placebo, reduced the incidence of CMV reactivation and disease in CMV-seropositive adults undergoing allogeneic HSCT.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of letermovir. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
letermovir (Prevymis)
SMC ID:
1338/18
Indication:
Prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant
Pharmaceutical company
MSD
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
11 March 2019